The Art of Drug Synthesis / Edition 1

The Art of Drug Synthesis / Edition 1

by Douglas S. Johnson
     
 

ISBN-10: 0471752150

ISBN-13: 9780471752158

Pub. Date: 07/09/2007

Publisher: Wiley

The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today. An introduction to each drug is

…  See more details below

Overview

The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today. An introduction to each drug is provided, as well as background to the biology, pharmacology, pharmacokinetics, and drug metabolism, followed by a detailed account of the drug synthesis.

  • Edited by prominent scientists working in drug discovery for Pfizer
  • Meets the needs of a growing community of researchers in pharmaceutical R&D
  • Provides a useful guide for practicing pharmaceutical scientists as well as a text for medicinal chemistry students
  • An excellent follow-up to the very successful first book by these editors, Contemporary Drug Synthesis, but with all new therapeutic categories and drugs discussed.

Product Details

ISBN-13:
9780471752158
Publisher:
Wiley
Publication date:
07/09/2007
Series:
Wiley Series on Drug Synthesis Series
Edition description:
New Edition
Pages:
296
Product dimensions:
7.22(w) x 10.20(h) x 0.87(d)

Table of Contents

Foreword.

Preface.

Contributors.

1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY (John A. Lowe, III).

1.1 Introduction.

1.2 Hurdles in the Drug Discovery Process.

1.3 The Tools of Medicinal Chemistry.

1.3.1 In Silico Modeling.

1.3.2 Structure-Based Drug Design (SBDD).

1.4 The Role of Synthetic Chemistry in Drug Discovery.

References.

2 PROCESS RESEARCH: HOW MUCH? HOW SOON? (Neal G. Anderson).

2.1 Introduction.

2.2 Considerations for Successful Scale-up to Tox Batches and Phase I Material.

2.3 Considerations for Phase 2 Material and Beyond.

2.3.1 Reagent Selection.

2.3.2 Solvent Selection.

2.3.3 Unit Operations.

2.3.4 Developing Simple, Effective, Efficient Work-ups and Isolations.

2.3.5 The Importance of Physical States.

2.3.6 Route Design and Process Optimization to Minimize COG.

2.4 Summary.

References.

I CANCER AND INFECTIOUS DISEASES.

3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) (Jie Jack Li).

3.1 Introduction.

3.2 Synthesis of Exemestane.

3.3 Synthesis of Anastrozole.

3.4 Synthesis of Letrozole.

References.

4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) (Chris Limberakis).

4.1 Introduction.

4.1.1 Mechanism of Action.

4.1.2 Modes of Resistance.

4.1.3 Structure–Activity Relationship (SAR) and Structure–Toxicity Relationship (STR).

4.1.4 Pharmacokinetics.

4.1.5 Synthetic Approaches.

4.2 Levofloxacin.

4.3 Moxifloxacin.

4.4 Gemifloxacin.

4.5 Garenoxacin (T-3811): A Promising Clinical Candidate.

References.

5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) (Andrew S. Bell).

5.1 Introduction.

5.2 Synthesis of Itraconazole.

5.3 Synthesis of Fluconazole.

5.4 Synthesis of Voriconazole.

5.5 Synthesis of Fosfluconazole.

References.

6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS (Arthur Harms).

6.1 Introduction.

6.2 Synthesis of Nevirapine.

6.3 Synthesis of Efavirenz.

6.4 Synthesis of Delavirdine Mesylate.

References.

7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) (Douglas S. Johnson and Jie Jack Li).

7.1 Introduction.

7.1.1 Relenza.

7.1.2 Tamiflu.

7.2 Synthesis of Oseltamivir Phosphate (Tamiflu).

7.3 Synthesis of Zanamivir (Relenza).

References.

II CARDIOVASCULAR AND METABOLIC DISEASES.

8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES (Jin Li).

8.1 Introduction.

8.1.1 Insulin.

8.1.2 Sulfonylurea Drugs.

8.1.3 Meglitinides.

8.1.4 Biguanides.

8.1.5 Alpha-Glucosidase Inhibitors.

8.1.6 Thiazolidinediones.

8.2 Synthesis of Rosiglitazone.

8.3 Synthesis of Pioglitazone.

8.4 Synthesis of Muraglitazar.

References.

9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION (Larry Yet).

9.1 Introduction.

9.2 Losartan Potassium.

9.2.1 Introduction to Losartan Potassium.

9.2.2 Synthesis of Losartan Potassium.

9.3 Valsartan.

9.3.1 Introduction to Valsartan.

9.3.2 Synthesis of Valsartan.

9.4 Irbesartan.

9.4.1 Introduction to Irbesartan.

9.4.2 Synthesis of Irbesartan.

9.5 Candesartan Cilexetil.

9.5.1 Introduction to Candesartan Cilexetil.

9.5.2 Synthesis of Candesartan Cilexetil.

9.6 Olmesartan Medoxomil.

9.6.1 Introduction to Olmesartan Medoxomil.

9.6.2 Synthesis of Olmesartan Medoxomil.

9.7 Eprosartan Mesylate.

9.7.1 Introduction to Eprosartan Mesylate.

9.7.2 Synthesis of Eprosartan Mesylate.

9.8 Telmisartan.

9.8.1 Introduction to Telmisartan.

9.8.2 Synthesis of Telmisartan.

References.

10 LEADING ACE INHIBITORS FOR HYPERTENSION (Victor J. Cee and Edward J. Olhava).

10.1 Introduction.

10.2 Synthesis of Enalapril Maleate.

10.3 Synthesis of Lisinopril.

10.4 Synthesis of Quinapril.

10.5 Synthesis of Benazepril.

10.6 Synthesis of Ramipril.

10.7 Synthesis of Fosinopril Sodium.

References.

11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION (Daniel P. Christen).

11.1 Introduction.

11.2 Synthesis of Nifedipine (Adalatw).

11.3 Synthesis of Felodepine (Plendilw).

11.4 Synthesis of Amlodipine Besylate (Norvascw).

11.5 Synthesis of Azelnidipine (Calblockw).

References.

12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS (Jeffrey A. Pfefferkorn).

12.1 Introduction.

12.2 Synthesis of Fluvastatin (Lescolw).

12.3 Synthesis of Rosuvastatin (Crestorw).

12.4 Synthesis of Pitavastatin (Livalow).

References.

13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) (Stuart B. Rosenblum).

13.1 Introduction.

13.2 Discovery Path to Ezetimibe.

13.3 Synthesis of Ezetimibe (Zetia).

References.

III CENTRAL NERVOUS SYSTEM DISEASES.

14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION (Marta Piñeiro-Núñez)

14.1 Introduction.

14.2 Synthesis of Venlafaxine.

14.3 Synthesis of Milnacipran.

14.4 Synthesis of Duloxetine.

References.

15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON (Peter R. Guzzo).

15.1 Introduction.

15.2 Synthesis of Zolpidem.

15.3 Synthesis of Zaleplon.

15.4 Synthesis of Eszopiclone.

15.5 Synthesis of Indiplon.

References.

16 a2d LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) (Po-Wai Yuen).

16.1 Introduction.

16.2 Synthesis of Gabapentin.

16.3 Synthesis of Pregabalin.

References.

17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) (David L. Gray).

17.1 Introduction.

17.1.1 Stimulant versus Nonstimulants.

17.2 Synthesis of Amphetamine.

17.2.1 Pharmacokinetic Properties of d- and l-Amphetamine.

17.2.2 Chiral Synthesis of Amphetamine.

17.3 Synthesis of Methylphenidate.

17.3.1 Methylphenidate Formulations.

17.3.2 Chiral Synthesis of Methylphenidate.

17.4 Synthesis of Atomoxetine.

References.

Index.

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >